16 Poliomyelitis

16.5 Recommended immunisation schedule

16.5.1 Usual childhood schedule

A primary course of poliomyelitis is given as DTaP-IPV-HepB/Hib at ages 6 weeks, 3 months and 5 months, followed by a booster dose given as DTaP-IPV at age 4 years.

16.5.2 Preterm infantsTop

Preterm infants who are still in hospital at age 6 weeks should receive IPV as DTaP-IPV-HepB/Hib, as per the Schedule, at the usual chronological age.

16.5.3 Unimmunised adults and childrenTop

For partially immunised or previously unimmunised individuals, a primary immunisation course consists of three doses of IPV-containing vaccine (funded). The recommended interval is four weeks between the first two doses, followed by the third dose approximately six months later (see Appendix 2). However, if necessary they may be given with a minimum of four weeks between doses.

If a course of vaccine is interrupted, it may be resumed without repeating prior doses. A booster may be given if 10 years have elapsed since the last dose and exposure is possible (eg, in the case of a traveller to an area where the virus circulates; this is not funded).

If a child who began a course of OPV in another country moves to New Zealand, they can switch to IPV. It is not necessary in this situation to start the full IPV series, and it is acceptable to continue the series using IPV for the final doses.

Note: all immunosuppressed individuals and their household contacts may receive IPV. OPV was contraindicated in the immunosuppressed because of the risk of VAPP (see section 16.3.1). There is no risk of VAPP with IPV.

16.5.4 (Re-)vaccinationTop

Polio-containing vaccines are funded for (re-)vaccination of eligible patients, as follows.

DTaP-IPV-HepB/Hib (Infanrix-hexa; for children aged under 10 years) and DTaP-IPV (Infanrix-IPV) are funded for patients:

IPV (IPOL) is funded for patients following immunosuppression.

See also sections 4.2 and 4.3.

16.5.5 Recommendations for other groupsTop

Booster doses of IPV are recommended (but not funded) for:

There is no evidence for the need for routine boosters, but they are recommended to reduce any possible risk from waning immunity in situations of increased risk of exposure.